Search - tctmd.com

Displaying 141 - 160 of 236

Sort: Relevancy | Date

News Conference News SCCT 2019

CTA or Function Tests in High-risk Chest Pain and No Known CAD: Debate Goes On

Yael L. Maxwell

July 16, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EuroPCR 2019

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

L.A. McKeown

May 31, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

News Daily News

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Michael O'Riordan

May 13, 2019

News Daily News

Warning Signs: Many Cardiac-Arrest Victims Visited Doctors, Emergency Rooms Prior to Events

Yael L. Maxwell

May 10, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Daily News

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

L.A. McKeown

February 26, 2019

News Daily News

Long Bouts of Sedentary Time Linked to CVD Risk in Women

Michael O'Riordan

February 20, 2019

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

News Conference News AHA 2018

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

Advertisement

CTA or Function Tests in High-risk Chest Pain and No Known CAD: Debate Goes On

Microvascular Disease Quadruples Risk of Leg Amputation

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Warning Signs: Many Cardiac-Arrest Victims Visited Doctors, Emergency Rooms Prior to Events

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

Long Bouts of Sedentary Time Linked to CVD Risk in Women

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content